Back to top

Maxim upgrades Akari Therapeutics to Buy on AKTX-101 data, ADC M&A

As previously reported, Maxim upgraded Akari Therapeutics (AKTX) to Buy from Hold with a $30 price target. The firm attributes the upgrade to a com...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Akari Therapeutics PLC (AKTX)

Novartis AG (NVS)